Arrowhead Pharmaceuticals Announces New CFO Appointment

Arrowhead Pharmaceuticals ( (ARWR) ) just unveiled an update.

Arrowhead Pharmaceuticals announced the retirement of its Chief Financial Officer, Ken Myszkowski, effective May 13, 2025, after 16 years of service. He will continue as an employee adviser until January 31, 2026, to ensure a smooth transition. Daniel Apel, formerly of Walgreens Boots Alliance and Bayer, will succeed Myszkowski as CFO. Apel’s appointment comes as Arrowhead transitions from a development stage to a commercial stage, with plans to launch plozasiran pending regulatory approval. This leadership change is expected to support Arrowhead’s ambitious development and commercialization plans.

Spark’s Take on ARWR Stock

According to Spark, TipRanks’ AI Analyst, ARWR is a Neutral.

Arrowhead Pharmaceuticals has a challenging financial profile with negative profitability and cash flow metrics, as well as a bearish technical outlook. However, the positive sentiment from the recent earnings call, highlighted by a substantial collaboration with Sarepta Therapeutics and a strong cash position, provides potential for future growth. The stock’s valuation is currently unattractive due to negative earnings, but strategic initiatives and upcoming product launches could improve its financial standing.

To see Spark’s full report on ARWR stock, click here.

More about Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.

YTD Price Performance: -37.20%

Average Trading Volume: 2,049,839

Technical Sentiment Signal: Buy

Current Market Cap: $1.69B

Learn more about ARWR stock on TipRanks’ Stock Analysis page.